Key clinical point: The antihypertensive drug losartan appears safe to study further in the treatment of children with epidermolysis bullosa (EB).
Major finding: Sixty-five adverse events were reported; four were severe (two bacterial infections requiring hospitalization; two were a reduction in general health condition). There were early indications of reduced skin scarring/fibrosis.
Study details: A prospective, phase 1/2 nonrandomized, single-arm trial of the safety, tolerability, and efficacy of losartan in 29 children with recessive dystrophic EB (RDEB).
Disclosures: DEBRA International funded the study. Dr. Kiritsi received research support from Rheacell GmbH and honoraria or consultation fees from Amryt Pharma and Rheacell GmbH. She has received other support from DEBRA International, EB Research Partnership, Fritz Thyssen Stiftung, German Research Foundation (funding of research projects), and 3R Pharma Consulting and Midas Pharma GmbH (consultation for losartan new drug formulation).
Kiritsi D et al. EB 2020. Poster 47.